Sou Hu Cai Jing·2025-08-21 02:59Group 1 - Recent industry capital buybacks demonstrate confidence in industry development, with Heng Rui announcing a plan to repurchase A-shares worth 1 to 2 billion yuan for employee stock ownership plans [1] - The performance assessment indicators for the company include innovative drug sales revenue, the number of new molecular entity IND approvals, and the number of innovative drug NDA applications accepted, with unlocking ratios set at 100%, 90%, and 0% [1] - The Vice President of China Biopharmaceutical repurchased 1 million shares, reflecting confidence in the company's development [1] Group 2 - Continuous policy support for the healthy development of the industry is highlighted, with a key leader emphasizing the need for high-quality technological supply and policy support to enhance the biopharmaceutical industry's quality and innovation [1] - On August 11, the Hang Seng Hong Kong Stock Connect Innovative Drug Index was officially adjusted to exclude CXO, becoming a "pure" innovative drug index, which more accurately reflects the overall performance of China's innovative pharmaceutical companies [1] - Historical performance of the index is expected to improve significantly after the exclusion of CXO, with the Hang Seng Innovative Drug ETF (159316) being the only ETF product tracking this index [1]